New cocktail of drugs shows promise for Tough-to-Treat colorectal cancer
NCT ID NCT06967155
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 41 times
Summary
This phase 2 trial is testing a combination of four drugs—irinotecan, dabrafenib, trametinib, and either cetuximab or panitumumab—as a second-line treatment for people with metastatic colorectal cancer that has a BRAF V600E mutation. The study aims to see how well this drug mix shrinks tumors and controls the disease. About 23 participants will be followed for up to three years to monitor response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Blokhin's Russian Cancer Research Center
Moscow, Moscow, 115478, Russia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Irinotecan, dabrafenib, trametinib, and cetuximab or panitumumab
What this could lead to
If successful, this could offer a new second-line treatment option for people with a specific type of advanced colorectal cancer that has a BRAF mutation.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The drug combination can cause significant side effects, and it is not yet known if it will improve survival compared to existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.